GSK (GSK) Fundamental Analysis: Revenue, Earnings & Valuation

4.73 / 10

Netural

Fundamentally, GSK scores 4.73/10, featuring a low cost‑of‑sales ratio (27.6%) and healthy interest coverage (14.9), but modest YoY revenue growth (~4%). Profit‑to‑MV and asset‑to‑MV metrics are positive, supporting a fair but cautious view.

Analysis Checks(5/10)

Total operating revenue (YoY growth rate %)

Value4.11

Score1/3

Weight-1.83%

1M Return-0.48%

Days sales outstanding

Value78.83

Score1/3

Weight-5.78%

1M Return-1.61%

Accounts receivable turnover ratio

Value4.57

Score3/3

Weight-4.11%

1M Return-1.06%

Profit-MV

Value1.30

Score3/3

Weight49.28%

1M Return9.28%

PB-ROE

Value0.60

Score2/3

Weight32.98%

1M Return7.17%

Income tax / Total profit (%)

Value15.03

Score0/3

Weight-7.65%

1M Return-2.17%

Interest coverage ratio (EBIT / Interest expense) (%)

Value14.91

Score2/3

Weight-4.64%

1M Return-1.25%

Operating revenue (YoY growth rate %)

Value4.11

Score1/3

Weight-1.58%

1M Return-0.42%

Cost of sales ratio (%)

Value27.60

Score3/3

Weight5.01%

1M Return1.16%

Asset-MV

Value-0.55

Score1/3

Weight38.30%

1M Return6.70%

Is GSK fundamentally strong?

GSK scores 4.73/10 on fundamentals and holds a Fair valuation at present. Backed by its 39.36% ROE, 19.25% net margin, 14.40 P/E ratio, 5.16 P/B ratio, and 139.77% earnings growth, these metrics solidify its Netural investment rating.